Opportunities for differential diagnosis of vascular cognitive impairment and Alzheimer's disease at the predementia stage

The steadily increasing aging of the population is accompanied by a growing prevalence of cognitive impairment (CI) of varying severity. The main causes of CI are Alzheimer's disease (AD), vascular impairment, and their combination. It has been shown that establishing the exact etiology of CI is crucial for appropriate patient management and disease prognosis. The paper outlines current principles for the diagnosis and treatment of mild cognitive impairment (MCI) syndrome. It is demonstrated that the nosological structure of MCI generally corresponds to the etiology of dementia in the elderly. Early detection of CI at the MCI stage is important because timely diagnosis broadens the potential for secondary prevention and therapeutic intervention, which can delay or even prevent the onset of dementia.

A clinical observation is presented of a female patient with a polyfunctional amnestic type of MCI syndrome, with both vascular and neurodegenerative mechanisms considered as potential etiological factors. Examination of the cerebrospinal fluid revealed biomarkers of AD, which enabled a diagnosis of late-onset AD at the predementia stage. The paper also analyzes the capabilities of modern neuroprotective and symptomatic therapies for CI, and the role of choline alfoscerate and citicoline in CI treatment.

he discussion includes ways to improve patient adherence to CI treatment using newly available dosage forms such as Noocil (240 ml bottle, oral liquid form of citicoline) and Cerpehol (240 ml bottle, oral liquid form of choline alfoscerate), which can also be used in patients with swallowing difficulties.

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Feb;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. Epub 2022 Jan 6.

2. WHO: Global status report on the public health response to dementia. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240033245 (accessed 14.01.2024).

3. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024 May;20(5):3708-821. doi: 10.1002/alz.13809. Epub 2024 Apr 30.

4. Grishina DA, Lokshina AB, Sokolov EA. Management of patients with cognitive impairment in old age. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(6):118-24. doi: 10.14412/2074-2711-2024-6-118-124 (In Russ.)].

5. Cherdak MA, Mkhitaryan EA, Sharashkina NV, et al. Prevalence of cognitive impairment in older adults in the Russian Federation. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4-2):511. doi: 10.17116/jnevro20241240425 (In Russ.)].

6. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementia. 3rd ed. Moscow: MEDpress-inform; 2011. 374 p. (In Russ.)].

7. Lokshina AB, Grishina DA, Zakharov VV. Vascular cognitive impairment: issues of diagnosis and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):106-13. doi: 10.14412/2074-27112023- 2-106-113 (In Russ.)].

8. Grishina DA, Starchina YuA, Sokolov EA, Parfenov VA. Comparative efficacy of inhaled nitric oxide therapy (Tianox device) in mild cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(6):5360. doi: 10.14412/2074-2711-2024-6-53-60 (In Russ.)].

9. Parfenov VA, Grishina DA, Tyurina AYu. Alzheimer's disease: diagnosis and treatment, errors in patient management. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):95100. doi: 10.14412/2074-2711-2024-2-95-100 (In Russ.)].

10. Lokshina AB, Grishina DA, Obukhova AV. Early-onset Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):110-6. doi: 10.14412/2074-27112022-2-110-116 (In Russ.)].

11. Rundek T, Tolea M, Ariko T, et al. VascularCognitive Impairment (VCI). Neurotherapeutics. 2022 Jan;19(1):68-88. doi: 10.1007/s13311021-01170-y. Epub 2021 Dec 22.

12. Boyle PA, Yu L, Wilson RS, et al. Personspecifc contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018 Jan;83(1):74-83. doi: 10.1002/ana.25123

13. Parfenov VA, Zaharov VV, Preobrazhenskaja IS. Cognitive disorders. Moscow: Remedium; 2014 (In Russ.)].

14. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-35. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27.

15. Grishina DA, Lokshina AB. Issues of diagnosis and treatment of mild cognitive impairment. Meditsinskiy Sovet. 2022;16(21):46-53. doi: 10.21518/2079-701X-2022-16-21-46-53 (In Russ.)].

16. Lokshina AB, Zakharov VV, Grishina DA, et al. Heterogeneity of the mild cognitive impairment syndrome (specialized outpatient service data analysis). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):3441. doi: 10.14412/2074-2711-2021-3-34-41 (In Russ.)].

17. Dubois B, Villain N, Frisoni GB, et al.Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021 Jun;20(6):484-96. doi: 10.1016/S1474-4422(21)00066-1. Epub 2021 Apr 29.

18. Celle S, Boutet C, Annweiler C, et al. Leukoaraiosis and Gray Matter Volume Alteration in Older Adults: The PROOF Study. Front Neurosci. 2022 Jan 13;15:747569. doi: 10.3389/fnins.2021.747569

19. Lokshina AB, Grishina DA. Issues of management of patients with post-stroke cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(3):114-20. doi: 10.14412/2074-2711-2023-3-114-120 (In Russ.)].

20. Teng E, Leone-Friedman J, Lee GJ, et al.Similar verbal fluency patterns in amnestic mild cognitive impairment and Alzheimer's disease. Arch Clin Neuropsychol. 2013 Aug;28(5):400-10. doi: 10.1093/arclin/act039. Epub 2013 Jun 9.

21. Jack CR Jr, Andrews JS, Beach TG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024 Aug;20(8):5143-69. doi: 10.1002/alz.13859. Epub 2024 Jun 27.

22. Zakharov VV, Lokshina AV, Vakhnina NV. Combined therapy for Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika =Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):74-80. doi: 10.14412/2074-27112022-3-74-80 (In Russ.)].

23. Shevtsova KV, Rozhkov DO, Grishina DA, et al. Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(3):96-102. doi: 10.14412/2074-2711-2024-3-96-102 (In Russ.)].

24. Grishina DA, Khayalieva NA, Grinyuk VV, Tyurina AYu. Diagnosis of Alzheimer's disease by using biological markers in posterior cortical atrophy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):47-53. doi: 10.14412/2074-2711-2024-2-47-53 (In Russ.)].

25. Tkacheva ON, Yakhno NN, Neznanov NG, et al. Cognitive disorders in elderly and old people. Clinical recommendations. Moscow; 2024 (In Russ.)].

26. Fioravanti M, Yanagi M.Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000269. doi: 10.1002/14651858.CD000269.pub3

27. Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine. Curr Ther Res. 1992;52(5):741-52. doi: 10.1016/S0011393X(05)80518-1

28. Barbagallo Sangiorgi G, Barbagallo M,Giordano M, et al. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci. 1994 Jun 30;717:253-69. doi: 10.1111/j.1749-6632.1994.tb12095.x

29. Scapicchio PL. Revisiting cholinealphoscerate profile: a new, perspective, role in dementia? Int J Neurosci. 2013;123:444-9. doi: 10.3109/00207454.2013.765870. Epub2013 Feb 19

30. Amenta F, Carotenuto A, Fasanaro AM, et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment. J Alzheimers Dis. 2014;42 Suppl 3:S281-8. doi: 10.3233/JAD-140150

31. Carotenuto A, Rea R, Traini E, et al. The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. J Alzheimers Dis. 2017;56(2):805-15. doi: 10.3233/JAD-160675

32. Traini E, Carotenuto A, Fasanaro AM, Amenta F. Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial. J Alzheimers Dis. 2020;76(1):317-29. doi: 10.3233/JAD-190623

33. Abad-Santos F, Novalbos-Reina J, Gallego-Sandin S, Garcia AG. Tratamiento del deterioro cognitivo leve: utilidad de la citicolina [Treatment of mild cognitive impairment: value of citicoline]. Rev Neurol. 2002 Oct 1-15;35(7):675-82 (In Spanish).

34. Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016 Dec 23;63(S03):S1-S73.

35. Synoradzki K, Grieb P. Citicoline: A Superior Form of Choline? Nutrients. 2019 Jul 12;11(7):1569. doi: 10.3390/nu11071569

36. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-7. doi: 10.2147/CIA.S38420. Epub 2013 Feb 5.